市场调查报告书
商品编码
1287292
肺癌治疗市场 - 按类型(类癌、非小细胞和小细胞)、按疗法[(放射、免疫疗法(Durvalumab)、靶向(Bevacizumab)、化疗]、按终端用户(医院、专科诊所、家庭护理),全球预测,2023-2032年Lung Cancer Treatment Market - By Type (Carcinoid, Non-small & Small Cell), By Therapy [(Radiation, Immunotherapy (Durvalumab), Targeted (Bevacizumab), Chemotherapy], By End-user (Hospitals, Specialty Clinics, Homecare), Global Forecast, 2023-2032 |
全球肺癌治疗市场规模将在2023-2032年间大幅增长。由于全球城市化进程加快和工业增长,空气污染水平不断上升,导致肺癌发病率增加,促进了对其治疗的需求。根据世界卫生组织的预测,环境空气污染将导致16%的肺癌死亡,而空气污染可能导致全球约29%的肺癌死亡。疾病负担的增加提高了人们对其早期诊断和治疗的认识,以防止进一步的并发症,促进了市场的增长。
整个肺癌治疗市场根据类型、疗法、终端用户和地区进行细分。
根据类型,类癌的市场份额将在2032年之前呈现显著增长。越来越多的肺癌患病率和与之相关的高死亡率增加了对其治疗的需求。根据美国癌症协会的数据,美国每年报告约有2000至4500个肺类癌肿瘤。此外,诊断技术的改进和对类癌认识的提高,推动了接受这种疾病治疗的患者数量,从而增加了市场收入。
在治疗方面,化疗部分的肺癌治疗市场价值将在2032年之前获得巨大收益。基因组学和分子分析的进步使化疗的个性化医疗成为可能。通过在分子水平上分析病人的肿瘤,医生可以确定推动癌症生长的特定基因突变或生物标志物。这些信息有助于调整化疗方案,以针对这些特定的异常情况,提高治疗效果。
根据终端用户,专科诊所部分的肺癌治疗市场将在2023-2032年观察到可观的增长。尖端诊断设备的高可用性使专科诊所成为首选的医疗保健提供者。此外,这些设施处于有利地位,可以提供针对特定病人需求的个性化护理。它们提供全面的评估、分子剖析和临床试验的机会,确保病人得到最适当和有效的治疗方案。
从区域来看,欧洲肺癌治疗行业将在2023年至2032年期间以体面的复合年增长率增长。肺癌的高发病率增加了该地区对其治疗的需求。此外,勃林格殷格翰国际有限公司、默克公司等行业竞争者的强大存在,不断专注于开发先进的肺癌治疗方案,对区域市场增长产生了积极影响。此外,该地区现有医疗基础设施的快速扩张将刺激行业收入来源,直至2032年。
Global Lung Cancer Treatment Market size will grow substantially during 2023-2032. Rising air pollution levels due to accelerating urbanization and industrial growth worldwide have resulted in increased incidences of lung cancer, bolstering the need for its treatment. As per the WHO, ambient air pollution is projected to lead to 16% of lung cancer deaths, while air pollution may be responsible for around 29% of the deaths caused by lung cancer globally. The increasing disease burden has bolstered awareness about its early diagnosis and treatment to prevent further complications, contributing to market growth.
The overall lung cancer treatment market is segmented based on type, therapy, end-user, and region.
Based on type, the market share from the carcinoid segment will depict significant growth through 2032. Growing prevalence of lung cancer and high mortality rate associated with it has increased the need for its treatment. According to the American Cancer Society, the U.S. reports around 2,000 to 4,500 lung carcinoid tumors every year. Moreover, improved diagnostic techniques and the rising awareness of carcinoid tumors have propelled the number of patients undergoing treatment of this condition, thus, adding to market revenue.
In terms of therapy, the lung cancer treatment market value from the chemotherapy segment will accrue significant gains through 2032. Advances in genomics and molecular profiling have enabled personalized medicine in chemotherapy. By analyzing a patient's tumor at a molecular level, doctors can identify specific genetic mutations or biomarkers that drive the cancer's growth. This information helps tailor the chemotherapy regimen to target those specific abnormalities, increasing treatment effectiveness.
Based on end-user, the lung cancer treatment market from the specialty clinics segment will observe appreciable growth over 2023-2032. High availability of cutting-edge diagnostic equipment has made specialty clinics a preferred healthcare provider. Additionally, these facilities are well-positioned to provide personalized care tailored to specific patient needs. They offer comprehensive evaluations, molecular profiling, and access to clinical trials, ensuring that patients receive the most appropriate and effective treatment options.
Regionally, Europe lung cancer treatment industry will grow at a decent CAGR from 2023 to 2032. High incidence rate of lung cancer has increased the need for its treatment in the region. Moreover, a strong presence of industry contenders such as Boehringer Ingelheim International GmbH, Merck KGaA, and others constantly focusing on developing advanced treatment options for lung cancer is positively impacting the regional market growth. Additionally, the rapid expansion of the existing healthcare infrastructure in the region will stimulate industry revenue streams through 2032.